Arjmand et al in a recent letter to the editor emphasized the importance of various health and non–health-related factors that affect the caregiver–patient relationship. We thank Arjmand et al for their commentary; their contribution is welcome.
Erlotinib-related Corneal Melting
We read with interest the article entitled, “Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases” by Saint-Jean et al. The severity of ocular toxicities of epidermal growth factor (EGF) receptor i…
Axial Length and Diabetic Retinopathy
The study presented by Man et al contributes to our understanding of the pathophysiology of diabetic retinopathy (DR) by demonstrating, in a large clinical study, that eyes with longer axial length are less likely to have DR or diabetic macular edema. …
Author reply
We appreciate the interest shown by Jonna et al
in our article entitled “Cognitive Impairment in Age-related Macular Degeneration and Geographic Atrophy.” We are happy to respond to all their concerns related to our work.
This Issue At A Glance
Vinciguerra 等人 (p. 908) 分析了进展性圆锥角膜患者角膜胶原交联术 (CXL) 后 4 年的随访效果, 关注的焦点在于讨论术后疗效与年龄的关系. 他们发现, CXL 对所有年龄段患者在稳定扩张性疾病进展方面均有效, 而 18-39 岁患者可以获得更好的功能及形态学结果. 该研究包括 301 名患者 400 只眼, 分为 4 个年龄组: <18 岁, 18-29 岁, 30-39 岁及 ≥40 岁. 所有年龄组患者最佳矫正视力 (BCVA) 均有显著提高. 另外, 患者均表现出等效球镜及角膜地形图参数数值的下降, 包括拟似角膜曲率 1 (Simk 1), Simk 2, 表面不对称指数 (SAI), 相对区域指数 (OSI) 及不同区域指数 (DSI), 从而进一步证实了以往的报道, CXL 可以重塑角膜形态. 研究者的观察发现, 18-39 岁患者是 CXL 的最佳疗效反应者. 这一报告将有助于眼外科医生选择合适的病人并预测圆锥角膜患者 CXL 术后的效果.
Contents
Full Story →